WASHINGTON (Legal Newsline) – The Federal Trade Commission (FTC) and the U.S. Food and Drug Administration (FDA) announced Jan. 24 that they warned 11 marketers and distributors of opioid cessation products to stop making allegedly unproven claims about their products.
According to the FTC, the 11 companies illegally marketed their products with false claims about the efficacy of their products. All of the companies purportedly used online platforms to make the allegedly unproven claims.
Examples of alleged false marketing claims include: “Imagine a life without the irritability, cravings, restlessness, excitability, exhaustion and discomfort associated with the nightmare of addiction and withdrawal symptoms” and “Safe and effective natural supplements that work to ease many physical symptoms of opiate withdrawal,” according to an FTC release.
“Opioid addiction is a serious health epidemic that affects millions of Americans,” said acting FTC Chairman Maureen K. Ohlhausen in a statement. “Individuals and their loved ones who struggle with this disease need real help, not unproven treatments. We will continue to work together with the FDA to address this important issue.”
The 11 companies are their products are Opiate Freedom Center (Opiate Freedom 5-Pack); U4Life LLC (Mitadone); CalmSupport LLC (CalmSupport); TaperAid (TaperAid & TaperAid Complete); Medicus Holistic Alternatives LLC (Natracet); NutraCore Health Products LLC (Opiate Detox Pro); Healthy Healing LLC (Withdrawal Support); Soothedrawal Inc. (Soothedrawal); Choice Detox Center Inc. (Nofeel); GUNA Inc. (GUNA-ADDICT 1); and King Bio Inc. (AddictaPlex).